Multi-Omic characterization of the effects of Ocrelizumab in patients with relapsing-remitting multiple sclerosis.
Kornilov SA, Price ND, Gelinas R, Acosta J, Brunkow ME, Gervasi-Follmar T, Winger RC, Aldershoff D, Lausted C, Troisch P, Smith B, Heath JR, Repovic P, Cohan S, Magis AT.
Kornilov SA, et al. Among authors: smith b.
J Neurol Sci. 2024 Nov 10;467:123303. doi: 10.1016/j.jns.2024.123303. Online ahead of print.
J Neurol Sci. 2024.
PMID: 39561535